Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress.

Logan J, Wang GJ, Telang F, Fowler JS, Alexoff D, Zabroski J, Jayne M, Hubbard B, King P, Carter P, Shea C, Xu Y, Muench L, Schlyer D, Learned-Coughlin S, Cosson V, Volkow ND, Ding YS.

Nucl Med Biol. 2007 Aug;34(6):667-79. Epub 2007 Jun 8.

PMID:
17707807
2.

Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region.

Logan J, Ding YS, Lin KS, Pareto D, Fowler J, Biegon A.

Nucl Med Biol. 2005 Jul;32(5):531-42.

PMID:
15982584
3.

Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.

Gallezot JD, Weinzimmer D, Nabulsi N, Lin SF, Fowles K, Sandiego C, McCarthy TJ, Maguire RP, Carson RE, Ding YS.

Neuroimage. 2011 May 1;56(1):268-79. doi: 10.1016/j.neuroimage.2010.09.040. Epub 2010 Sep 30.

4.

Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.

Seneca N, Gulyás B, Varrone A, Schou M, Airaksinen A, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis RB, Halldin C.

Psychopharmacology (Berl). 2006 Sep;188(1):119-27. Epub 2006 Aug 4.

PMID:
16896954
5.

Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.

Ding YS, Naganawa M, Gallezot JD, Nabulsi N, Lin SF, Ropchan J, Weinzimmer D, McCarthy TJ, Carson RE, Huang Y, Laruelle M.

Neuroimage. 2014 Feb 1;86:164-71. doi: 10.1016/j.neuroimage.2013.08.001. Epub 2013 Aug 9.

PMID:
23933039
7.

PET Quantification of the Norepinephrine Transporter in Human Brain with (S,S)-18F-FMeNER-D2.

Moriguchi S, Kimura Y, Ichise M, Arakawa R, Takano H, Seki C, Ikoma Y, Takahata K, Nagashima T, Yamada M, Mimura M, Suhara T.

J Nucl Med. 2017 Jul;58(7):1140-1145. doi: 10.2967/jnumed.116.178913. Epub 2016 Dec 15.

PMID:
27980046
8.

Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INER.

Tavares AA, Barret O, Batis J, Alagille D, Koren A, Papin C, Kudej G, Nice K, Kordower JH, Cosgrove KP, Kloczynski T, Brenner E, Seibyl J, Tamagnan G.

Synapse. 2013 Jan;67(1):30-41. doi: 10.1002/syn.21613. Epub 2012 Oct 31.

PMID:
23042643
9.

Imaging human brown adipose tissue under room temperature conditions with (11)C-MRB, a selective norepinephrine transporter PET ligand.

Hwang JJ, Yeckel CW, Gallezot JD, Aguiar RB, Ersahin D, Gao H, Kapinos M, Nabulsi N, Huang Y, Cheng D, Carson RE, Sherwin R, Ding YS.

Metabolism. 2015 Jun;64(6):747-55. doi: 10.1016/j.metabol.2015.03.001. Epub 2015 Mar 5.

10.

PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT.

Ding YS, Singhal T, Planeta-Wilson B, Gallezot JD, Nabulsi N, Labaree D, Ropchan J, Henry S, Williams W, Carson RE, Neumeister A, Malison RT.

Synapse. 2010 Jan;64(1):30-8. doi: 10.1002/syn.20696.

11.

Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine.

Li CS, Potenza MN, Lee DE, Planeta B, Gallezot JD, Labaree D, Henry S, Nabulsi N, Sinha R, Ding YS, Carson RE, Neumeister A.

Neuroimage. 2014 Feb 1;86:306-10. doi: 10.1016/j.neuroimage.2013.10.004. Epub 2013 Oct 10.

12.

Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs.

Ding YS, Lin KS, Garza V, Carter P, Alexoff D, Logan J, Shea C, Xu Y, King P.

Synapse. 2003 Dec 15;50(4):345-52.

PMID:
14556239
13.

In vivo assessment of [11C]MRB as a prospective PET ligand for imaging the norepinephrine transporter.

Severance AJ, Milak MS, Kumar JSD, Prabhakaran J, Majo VJ, Simpson NR, Van Heertum RL, Arango V, Mann JJ, Parsey RV.

Eur J Nucl Med Mol Imaging. 2007 May;34(5):688-693. doi: 10.1007/s00259-006-0312-2. Epub 2006 Dec 19.

PMID:
17180600
14.

Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter.

Wilson AA, Johnson DP, Mozley D, Hussey D, Ginovart N, Nobrega J, Garcia A, Meyer J, Houle S.

Nucl Med Biol. 2003 Feb;30(2):85-92.

PMID:
12623106
15.

Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2.

Arakawa R, Okumura M, Ito H, Seki C, Takahashi H, Takano H, Nakao R, Suzuki K, Okubo Y, Halldin C, Suhara T.

J Nucl Med. 2008 Aug;49(8):1270-6. doi: 10.2967/jnumed.108.051292. Epub 2008 Jul 16.

16.

Mapping of the norepinephrine transporter in the human brain using PET with (S,S)-[18F]FMeNER-D2.

Takano A, Varrone A, Gulyás B, Karlsson P, Tauscher J, Halldin C.

Neuroimage. 2008 Aug 15;42(2):474-82. doi: 10.1016/j.neuroimage.2008.05.040. Epub 2008 Jul 9.

PMID:
18617423
17.

Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2).

Takano A, Gulyás B, Varrone A, Maguire RP, Halldin C.

Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1308-14. doi: 10.1007/s00259-009-1118-9. Epub 2009 Mar 20.

PMID:
19300997
19.

Synthesis of 11C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET.

Schou M, Pike VW, Sóvágó J, Gulyás B, Gallagher PT, Dobson DR, Walter MW, Rudyk H, Farde L, Halldin C.

Bioorg Med Chem. 2007 Jan 15;15(2):616-25. Epub 2006 Nov 2.

PMID:
17123820
20.

Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.

Zhou Y, Resnick SM, Ye W, Fan H, Holt DP, Klunk WE, Mathis CA, Dannals R, Wong DF.

Neuroimage. 2007 Jun;36(2):298-312. Epub 2007 Mar 16.

Supplemental Content

Support Center